RT Journal Article
T1 Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications.
A1 Caronna, E
A1 José Gallardo, V
A1 Alpuente, A
A1 Torres-Ferrus, M
A1 Sánchez-Mateo, N M
A1 Viguera-Romero, J
A1 López-Veloso, A C
A1 López-Bravo, A
A1 Gago-Veiga, A B
A1 Irimia Sieira, P
A1 Porta-Etessam, J
A1 Santos-Lasaosa, S
A1 Pozo-Rosich, P
A1 Spanish CGRP-COVID Study Group, 
K1 Anticuerpos monoclonales
K1 CGRP
K1 COVID-19
K1 Migraine
K1 Migraña
K1 Monoclonal antibodies
K1 SARS-CoV-2
AB CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/24374
UL https://hdl.handle.net/10668/24374
LA en
DS RISalud
RD Apr 11, 2025